Behind the
#Bronchiectasis in
#Systemic #Sclerosis.
#Prevalence and Risk Factors
Study Design and Population:
📋 Design: Observational, analytical, cross-sectional monocentric study, appropriate for prevalence and association analysis.
🧍♀️ Population: 92 SSc patients (ACR-EULAR 2013 criteria), excluding those with traction bronchiectasis. The sample size is moderate but limits statistical power.
Measurement and Bias
✔️ Strength: HRCT, a reliable diagnostic tool, enhances detection validity.
⚠️ Weakness: Limited details on exposure measurement methods for esophageal dysmotility and immunological features.
Statistical Analysis
📊 Tests (e.g., Mann-Whitney, Chi-square) are appropriate. However, absence of confidence intervals limits effect size interpretation.
📈 Key Results and Evidence Quality
#Prevalence:
🫁
#Bronchiectasis observed in 23% of SSc patients, highlighting pulmonary involvement beyond ILD.
Associations Identified:
➕
#Positive: Anti-CENP positivity (p=0.044) and secondary Sjogren’s syndrome (p=0.006).
➖
#Negative: ILD and immunosuppressants (p=0.032 and p=0.01).
#PulmonaryFunction
📉 No significant differences in DLCO or FVC/FVE1 between bronchiectasis and non-ILD patients, suggesting minimal functional impact.
💪Strengths
✅HRCT as a gold-standard imaging method.
✅Analysis stratified by ILD presence.
❌ Limitations
🔹Cross-sectional design limits causality.
🔹Lack of longitudinal data to assess progression.
🔹Generalizability affected by single-center setting.
🔹Potential confounding factors, e.g., infections, were not explored.
💡 Conclusions and Additional Findings
1⃣Primary Insights:
▪️Bronchiectasis is an independent manifestation of SSc.
▪️Higher prevalence in secondary Sjogren’s suggests a sicca-related mechanism rather than autoimmune antibodies like SSA.
2⃣Additional Observations
▪️Immunosuppressants negatively associated with bronchiectasis, suggesting therapeutic or confounding effects.
▪️Asymptomatic progression underscores the need for HRCT screening.
🩺 Implications for Practice and Research
Clinical Practice
🔍 Routine HRCT for SSc patients, even in asymptomatic cases.
🩹 Targeted management for secondary Sjogren’s patients.
Future Research
📅 Longitudinal studies to explore natural history and clinical outcomes.
🧫 Investigate infectious or environmental contributions.
bit.ly/48YTpht